Regulus Therapeutics Stock Analysis
| RGLS Stock | USD 1.63 0.02 1.24% |
Regulus Therapeutics is undervalued with Real Value of 2.72 and Target Price of 6.25. The main objective of Regulus Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Regulus Therapeutics is worth, separate from its market price. There are two main types of Regulus Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Regulus Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Regulus Therapeutics is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Regulus Stock trading window is adjusted to America/New York timezone.
Regulus |
Regulus Stock Analysis Notes
About 88.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.21. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Regulus Therapeutics recorded a loss per share of 1.02. The entity last dividend was issued on the 4th of October 2018. The firm had 1:10 split on the 29th of June 2022. Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. Regulus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. To find out more about Regulus Therapeutics contact Joseph MBA at 858 202 6300 or learn more at https://www.regulusrx.com.Regulus Therapeutics Investment Alerts
| Regulus Therapeutics may become a speculative penny stock | |
| Regulus Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (30.04 M) with loss before overhead, payroll, taxes, and interest of (18.41 M). | |
| Regulus Therapeutics currently holds about 47.53 M in cash with (26.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.25, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Regulus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Top TSX Penny Stocks To Watch In November 2024 |
Regulus Therapeutics Upcoming and Recent Events
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Regulus Largest EPS Surprises
Earnings surprises can significantly impact Regulus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.15 | -0.17 | -0.02 | 13 | ||
2024-11-07 | 2024-09-30 | -0.17 | -0.21 | -0.04 | 23 | ||
2024-05-09 | 2024-03-31 | -0.22 | -0.29 | -0.07 | 31 |
Regulus Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Alyeska Investment Group, L.p. | 2024-09-30 | 1 M | State Street Corp | 2024-09-30 | 1 M | Woodline Partners Lp | 2024-09-30 | 948.7 K | Dafna Capital Management Llc | 2024-09-30 | 895.2 K | Point72 Asset Management, L.p. | 2024-09-30 | 893.8 K | Ra Capital Management, Llc | 2024-09-30 | 766.8 K | Opaleye Management Inc | 2024-09-30 | 535 K | Northern Trust Corp | 2024-09-30 | 497.3 K | Cvi Holdings Llc | 2024-06-30 | 401 K | Federated Hermes Inc | 2024-09-30 | 12.9 M | Nea Management Company, Llc | 2024-09-30 | 6.5 M |
Regulus Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 107.42 M.Regulus Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.98) | (1.03) | |
| Return On Capital Employed | (1.40) | (1.47) | |
| Return On Assets | (0.98) | (1.03) | |
| Return On Equity | (1.42) | (1.35) |
Management Efficiency
Regulus Therapeutics has return on total asset (ROA) of (0.4239) % which means that it has lost $0.4239 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7236) %, meaning that it created substantial loss on money invested by shareholders. Regulus Therapeutics' management efficiency ratios could be used to measure how well Regulus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.03 in 2024. Return On Capital Employed is likely to drop to -1.47 in 2024. At this time, Regulus Therapeutics' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 4.4 M in 2024, whereas Other Current Assets are likely to drop slightly above 1.3 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.12 | 1.17 | |
| Tangible Book Value Per Share | 1.12 | 1.17 | |
| Enterprise Value Over EBITDA | (0.09) | (0.10) | |
| Price Book Value Ratio | 1.15 | 1.75 | |
| Enterprise Value Multiple | (0.09) | (0.10) | |
| Price Fair Value | 1.15 | 1.75 | |
| Enterprise Value | 3.4 M | 3.2 M |
The decision-making processes within Regulus Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta 1.628 | Return On Assets (0.42) | Return On Equity (0.72) |
Technical Drivers
As of the 2nd of December, Regulus Therapeutics holds the Coefficient Of Variation of 10975.75, risk adjusted performance of 0.0151, and Semi Deviation of 3.81. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Regulus Therapeutics, as well as the relationship between them. Please check Regulus Therapeutics downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Regulus Therapeutics is priced some-what accurately, providing market reflects its current price of 1.63 per share. Please also confirm Regulus Therapeutics total risk alpha, which is currently at (0.66) to check out the company can sustain itself at a future point.Regulus Therapeutics Price Movement Analysis
The output start index for this execution was twenty-seven with a total number of output elements of thirty-four. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Regulus Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Regulus Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Regulus Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Regulus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Regulus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Regulus Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Regulus Therapeutics Outstanding Bonds
Regulus Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Regulus Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Regulus bonds can be classified according to their maturity, which is the date when Regulus Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| US75913MAA71 Corp BondUS75913MAA71 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| RF 575 Corp BondUS7591EPAR12 | View |
Regulus Therapeutics Predictive Daily Indicators
Regulus Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Regulus Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 8428.08 | |||
| Daily Balance Of Power | 0.2857 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 1.63 | |||
| Day Typical Price | 1.63 | |||
| Price Action Indicator | 0.015 | |||
| Period Momentum Indicator | 0.02 |
Regulus Therapeutics Forecast Models
Regulus Therapeutics' time-series forecasting models are one of many Regulus Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Regulus Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Regulus Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Regulus Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Regulus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Regulus Therapeutics. By using and applying Regulus Stock analysis, traders can create a robust methodology for identifying Regulus entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (1.81) | (1.90) | |
| Operating Profit Margin | (1.63) | (1.71) | |
| Net Loss | (1.75) | (1.84) | |
| Gross Profit Margin | 1.15 | 1.21 |
Current Regulus Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Regulus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Regulus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 6.25 | Strong Buy | 6 | Odds |
Most Regulus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Regulus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Regulus Therapeutics, talking to its executives and customers, or listening to Regulus conference calls.
Regulus Stock Analysis Indicators
Regulus Therapeutics stock analysis indicators help investors evaluate how Regulus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Regulus Therapeutics shares will generate the highest return on investment. By understating and applying Regulus Therapeutics stock analysis, traders can identify Regulus Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 24.3 M | |
| Common Stock Shares Outstanding | 19 M | |
| Total Stockholder Equity | 21.2 M | |
| Tax Provision | 1000.00 | |
| Property Plant And Equipment Net | 2.5 M | |
| Cash And Short Term Investments | 23.8 M | |
| Cash | 23.8 M | |
| Accounts Payable | 204 K | |
| Net Debt | -21.4 M | |
| 50 Day M A | 1.528 | |
| Total Current Liabilities | 8.5 M | |
| Other Operating Expenses | 31.1 M | |
| Non Current Assets Total | 2.6 M | |
| Non Currrent Assets Other | 3 M | |
| Stock Based Compensation | 2.8 M |
Additional Tools for Regulus Stock Analysis
When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.